학술논문
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
Document Type
Article
Author
Source
In: BioDrugs . (BioDrugs, November 2023, 37(6):873-889)
Subject
Language
English
ISSN
1179190X
11738804
11738804